John Pacifico joined Canaan's healthcare venture team at age 20 and has since served as CEO of two biosurgical companies (ORTHOCON and Abyrx) that he helped launch from the investor side, giving him hands-on company-building experience alongside traditional venture investing. He has also invented medical products that achieved FDA clearance for surgical use and helped lead fundraising for multiple Canaan vehicles, bringing more than $1.75B of capital into the firm.

• Deep focus on life sciences and medical technology, specifically highlighting advancements in orthopedic surgery and treatments for neurodegenerative conditions. He frequently posts updates on clinical trials, such as progress made by Transposon in treating ALS and other brain disorders.
• Appreciation for tangible operational milestones and regulatory achievements rather than just fundraising hype. He specifically championed the Abyrx team for surpassing thirty thousand successful bone putty implants across various surgical disciplines like trauma and sports medicine.
• Recognition of the broader operational team required to build a company, extending gratitude beyond just the founders to include sales forces, commercial partners, and end-users. He explicitly thanked surgeon customers and his sales leadership when discussing the growth of his portfolio companies.
• Valuation of long-term relationships and persistence in venture capital. He expressed pride during the acquisition of Relievant Medsystems by noting he had first evaluated and invested in the company nearly two decades prior to their exit.
• Consistent demonstration of patriotism and respect for military service. He regularly utilizes his platform to honor veterans and active duty personnel on national holidays, indicating a strong alignment with service-oriented values.